Q-linea (QLINEA) Q3 2025 earnings summary

Executive summary

• Record consumables demand in Q3 2025, driven by new instrument installations and increased usage, with a growing commercial pipeline in the US, EMEA, Asia, and Latin America.

• Internal production of consumables is now fully in-house, reducing costs and supporting higher volumes.

• Operational costs are decreasing, with a strategic focus on market-centric activities and a plan to reduce the cost base by an additional 10%.

• Priorities for Q4 include converting contracts to reach 30 ASTar units, supporting Pheno user conversions, and expanding into new markets.

• Commercial discussions are active in over 15 countries, with robust pipelines and first evaluations planned in Asia, Latin America, and the Middle East.

Financial highlights

• Net sales for Q3 2025 reached SEK 3.5 million, with Jan–Sep 2025 sales at SEK 8.2 million, representing 370% year-over-year growth.

• Record month for recurring income and consumables in September.

• OPEX reduced, with a target of a 10% reduction from the current SEK 13 million per month, aiming for SEK 11.3–11.8 million per month in 2026.

• Employee count reduced from 150 in 2023 to 83 by end of Q3 2025, lowering personnel expenses.

• Operating loss (EBIT) improved to SEK -40.7 million in Q3 2025 from SEK -41.1 million in Q3 2024.

Outlook and guidance

• Targeting 30 ASTar system placements by year-end, with a strong Q4 expected due to capital purchase cycles and competitor exits.

• Upper range of 30–40 placements now unlikely due to a court decision in Italy, but 30 remains achievable.

• FDA submission for US version 2 menu expected in H1 2026; majority of US pipeline customers await this clearance.

• Targeting breakeven during 2027, supported by cost reductions and increased recurring revenues.